Format

Send to

Choose Destination
Int J Infect Dis. 2015 Mar;32:46-9. doi: 10.1016/j.ijid.2014.12.039.

Tackling the tuberculosis epidemic in sub-Saharan Africa--unique opportunities arising from the second European Developing Countries Clinical Trials Partnership (EDCTP) programme 2015-2024.

Author information

1
Center for Clinical Microbiology, Division of Infection and Immunity, University College London, NIHR Biomedical Research Centre, at UCLHospital, London, United Kingdom.
2
Department of Infectious Diseases and Clinical Microbiology, Aarhus University Hospital Skejby, Aarhus, Denmark.
3
European Developing Countries Clinical trials Partnership, Cape Town, South Africa.
4
Kenya Medical Research Institute (KEMRI), Nairobi, Kenya. Electronic address: chakaya.jm@gmail.com.

Abstract

Tuberculosis (TB) today remains a global emergency affecting 9.0 million people globally. The African Region bears the highest global TB/HIV burden and over 50% of TB cases in SSA are co-infected with HIV. An estimated 1.5 million died from the TB globally in 2013. A large majority of the 360,000 HIV-positive TB cases who died were from sub-Saharan Africa. Research and development is an important pillar of the WHO post-2015 global TB strategy. Advances in development of diagnostics, drugs, host-directed therapies, and vaccines will require evaluation under field conditions through multi-centre clinical trials at different geographical locations. Thus it is critically important that these evaluations are fully supported by all African governments and the capacity, trained staff and infrastructure required to perform the research and evaluations is built and made available. This viewpoint article reviews the opportunities provided by recently launched second programme (2015-2024) of the European & Developing Countries Clinical Trials Partnership (EDCTP2) for tackling the TB epidemic in Africa through its magnanimous portfolio. The unique opportunities provided by EDCTP2 for leadership of scientific research in TB and other diseases fully devolving to Africa are also covered.

KEYWORDS:

Capacity Development; Control; EDCTP; Epidemiology; HIV; Research; Tuberculosis (TB); sub-Saharan Africa

PMID:
25809755
DOI:
10.1016/j.ijid.2014.12.039
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center